Sanghyeon Yun

This inventor holds 7 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Intocell, Inc., Y-Biologics Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sanghyeon Yun. Retrieved from https://idiyas.com/inventor/sanghyeon-yun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 15.6

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12551570 - Compounds comprising cleavable linker and uses thereof (2026-02-17),

2. 12479927 - Compounds comprising cleavable linker and uses thereof (2025-11-25),

3. 12274898 - Substituted benzodiazepines as antibody-drug conjugates (2025-04-14),

4. 12168060 - Antibody-drug conjugates comprising anti-B7-H3 antibodies (2024-12-17),

5. 11807628 - Benzodiazepine derivatives and uses thereof (2023-11-07),

6. 11753431 - Compounds comprising cleavable linker and uses thereof (2023-09-12),

7. 11084801 - Benzodiazepine derivatives and uses thereof (2021-08-10),

Title: Sanghyeon Yun: Innovator in Antibody-Drug Conjugates

Introduction

Sanghyeon Yun is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of antibody-drug conjugates. With a total of 7 patents, his work has the potential to impact therapeutic approaches in various medical applications.

Latest Patents

Sanghyeon Yun's latest patents include innovative compounds and compositions. One of his notable patents is for substituted benzodiazepines as antibody-drug conjugates. This patent provides compounds that can be utilized in advanced therapeutic strategies. Another significant patent involves antibody-drug conjugates comprising anti-B7-H3 antibodies. This disclosure relates to ADCs where active agents are conjugated to an anti-B7-H3 antibody through a specialized linker. The invention also covers monoclonal antibodies and their variants that specifically bind to B7-H3, along with methods for their therapeutic, diagnostic, and prophylactic applications.

Career Highlights

Throughout his career, Sanghyeon Yun has worked with various companies, including Intocell, Inc. and Y-Biologics Inc. His experience in these organizations has allowed him to refine his expertise in the field of biochemistry and drug development.

Collaborations

Sanghyeon Yun has collaborated with notable colleagues, including Taekyo Park and Sung Ho Woo. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Sanghyeon Yun is a distinguished inventor whose work in antibody-drug conjugates is paving the way for innovative therapeutic solutions. His contributions to the field are significant and continue to influence advancements in medical science.

Profile summary based on public USPTO records.